Navigation Links
OncoSec Medical to Present Data at DNA Vaccines 2012 Conference
Date:12/4/2012

 developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical stud
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 ... has announced the addition of the ... to their offering.      (Logo: ... of chromosomes using molecular biology to understand ... chromosomes. It plays a crucial role in ...
(Date:9/18/2014)... , Sept. 18, 2014  Low T ... committee meeting in Hyattsville, Maryland ... to assess the proper patient population for testosterone ... cardiovascular risk associated with TRT. Examining recent claims from ... found that "available epidemiological studies do not provide ...
(Date:9/18/2014)... CITY, Kan. , Sept. 18, 2014 /PRNewswire/ ... a pet therapeutics company focused on licensing, developing ... today announced the full exercise of the underwriters, ... stock in connection with the company,s previously announced ...  All of the shares are being offered by ...
Breaking Medicine Technology:Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
(Date:9/18/2014)... 19, 2014 Today, Zane Benefits, the ... why to switch employees to individual health insurance. ... be more familiar with traditional, group health insurance, there ... employees happier. , The new article provides the ... health insurance rather than group health insurance, and why ...
(Date:9/18/2014)... (PRWEB) September 19, 2014 Reduce bags ... ingredients made just for these issues in a serum. ... Haloxyl and Eyeliss," says Kathy Heshelow, founder of Sublime ... circulation and boosting collagen, to improve the eye area." ... serum for wrinkles, dark circles and bags at ...
(Date:9/18/2014)... 19, 2014 When Mary Ann Thompson and Mathieu ... who live in Bali, Indonesia with their son, Isaac, said there ... two met at Mercy College in 2001 when Thompson was an ... was a graduate student at the time, was French and so ... and migrated to the United States when she was 7 years ...
(Date:9/18/2014)... 18, 2014 Defendants in more ... currently pending in Pennsylvania’s Philadelphia Court of Common ... on behalf of out-of-state plaintiffs dismissed, Bernstein Liebhard ... 11th, the defendants maintain that circumstances surrounding the ... lawsuits have no connection to Pennsylvania. The filings ...
(Date:9/18/2014)... Active Aging Week is a week-long observance ... members of society and promotes the benefits of leading ... a boutique retirement community located at 1200 Overlook Drive, ... of Cyber-Seniors - a humorous and heartwarming documentary. , ... this great film,” says Thomas Cloutier, Executive Director for ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Why Employees Are Happier with Individual Health Insurance 2Health News:The Secret to Improving Under-Eye Skin: 30% Off Sale and Report on Ingredients Ends Tonight on the Face Whisperer® Advanced Eye Gel 2Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:In Support of Active Aging Week, a Lake Oswego Retirement Community Will Get a Sneak Peek at an Inter-Generational Documentary – Cyber-Seniors 2
... Rehab MarketDETROIT, March 10 David Glancy, a complex ... has joined Alliance Seating & Mobility (ASM), ... companies. Glancy is an Assistive Technology Professional ... and provides power mobility solutions for pediatrics and adults ...
... WASHINGTON, March 10 To guide healthcare systems in ... the National Quality Forum (NQF) is releasing its 2009 ... pace of adoption of Safe Practices nationwide, a year-long ... Practices implementation strategies and commentary from experts in the ...
... soar past $2.5 trillion and more than 47 million people ... medical options to ensure health care reform is successful, argues ... Americans die each year because of their lack of insurance, ... that save very few lives or yield only a few ...
... of fondness and relief. Fondness for the good memories, and relief ... gossip, SATs, fights with parents is behind us. ... that even stressful times from the teenage years exact a physical ... , Andrew J. Fuligni, a professor of psychiatry at the ...
... ROCHESTER, Minn., March 10 Here are highlights from ... . You may cite this publication as often as ... attribution is required. Reprinting is allowed ... your editorial policies permit: Visit www.bookstore.mayoclinic.com or ...
... CPC of America, Inc. (OTC Bulletin Board: ... therapeutic devices that enhance the quality of patient ... is actively pursuing the development of proprietary polyethylene ... global commercialization strategy for MedClose(TM). MedClose(TM) is ...
Cached Medicine News:Health News:Veteran Rehab Specialist, David Glancy, Joins Fast-Growing Alliance Seating & Mobility in Michigan 2Health News:'Patient Safety Can't Wait' - NQF Calls for Faster Spread of Safe Practices 2Health News:'Patient Safety Can't Wait' - NQF Calls for Faster Spread of Safe Practices 3Health News:'Patient Safety Can't Wait' - NQF Calls for Faster Spread of Safe Practices 4Health News:Limited resources, unlimited needs: Americans should ration health care, says MSU ethicist 2Health News:Limited resources, unlimited needs: Americans should ration health care, says MSU ethicist 3Health News:Teenage stress has implications for adult health 2Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 2Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 3Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 4Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 5Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 6Health News:CPC Pursues Development of Proprietary Synthetic Sealants as part of MedClose(TM) Global Commercialization 2Health News:CPC Pursues Development of Proprietary Synthetic Sealants as part of MedClose(TM) Global Commercialization 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: